Abbott Laboratories

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, ABT is priced at $102.87, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, ABT's ROE is +0.13%, compared to BSX-PA's ROE of +0.13%. Regarding short-term risk, ABT is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check BSX-PA's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, SYK has a market cap of 126.9B. Regarding current trading prices, ABT is priced at $102.87, while SYK trades at $331.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas SYK's P/E ratio is 39.47. In terms of profitability, ABT's ROE is +0.13%, compared to SYK's ROE of +0.15%. Regarding short-term risk, ABT is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check SYK's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, MDT has a market cap of 111.2B. Regarding current trading prices, ABT is priced at $102.87, while MDT trades at $86.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas MDT's P/E ratio is 24.20. In terms of profitability, ABT's ROE is +0.13%, compared to MDT's ROE of +0.10%. Regarding short-term risk, ABT is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check MDT's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, BSX has a market cap of 93.2B. Regarding current trading prices, ABT is priced at $102.87, while BSX trades at $62.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas BSX's P/E ratio is 32.38. In terms of profitability, ABT's ROE is +0.13%, compared to BSX's ROE of +0.13%. Regarding short-term risk, ABT is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check BSX's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, EW has a market cap of 47.1B. Regarding current trading prices, ABT is priced at $102.87, while EW trades at $81.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas EW's P/E ratio is 44.78. In terms of profitability, ABT's ROE is +0.13%, compared to EW's ROE of +0.10%. Regarding short-term risk, ABT is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check EW's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, BRKRP has a market cap of 44B. Regarding current trading prices, ABT is priced at $102.87, while BRKRP trades at $290.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas BRKRP's P/E ratio is N/A. In terms of profitability, ABT's ROE is +0.13%, compared to BRKRP's ROE of -0.00%. Regarding short-term risk, ABT is less volatile compared to BRKRP. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check BRKRP's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, PHG has a market cap of 26B. Regarding current trading prices, ABT is priced at $102.87, while PHG trades at $27.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas PHG's P/E ratio is 25.10. In terms of profitability, ABT's ROE is +0.13%, compared to PHG's ROE of +0.08%. Regarding short-term risk, ABT is less volatile compared to PHG. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check PHG's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, DXCM has a market cap of 24.3B. Regarding current trading prices, ABT is priced at $102.87, while DXCM trades at $62.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas DXCM's P/E ratio is 29.77. In terms of profitability, ABT's ROE is +0.13%, compared to DXCM's ROE of +0.32%. Regarding short-term risk, ABT is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check DXCM's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, STE has a market cap of 21.5B. Regarding current trading prices, ABT is priced at $102.87, while STE trades at $218.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas STE's P/E ratio is 30.50. In terms of profitability, ABT's ROE is +0.13%, compared to STE's ROE of +0.10%. Regarding short-term risk, ABT is less volatile compared to STE. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check STE's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, ZBH has a market cap of 18B. Regarding current trading prices, ABT is priced at $102.87, while ZBH trades at $90.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas ZBH's P/E ratio is 25.60. In terms of profitability, ABT's ROE is +0.13%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, ABT is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check ZBH's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, ABT is priced at $102.87, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas ABMD's P/E ratio is 65.36. In terms of profitability, ABT's ROE is +0.13%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, ABT is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.Check ABMD's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, PODD has a market cap of 14.4B. Regarding current trading prices, ABT is priced at $102.87, while PODD trades at $204.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas PODD's P/E ratio is 58.71. In terms of profitability, ABT's ROE is +0.13%, compared to PODD's ROE of +0.17%. Regarding short-term risk, ABT is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check PODD's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, SNN has a market cap of 13.7B. Regarding current trading prices, ABT is priced at $102.87, while SNN trades at $32.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas SNN's P/E ratio is 22.47. In terms of profitability, ABT's ROE is +0.13%, compared to SNN's ROE of +0.12%. Regarding short-term risk, ABT is less volatile compared to SNN. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check SNN's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, PEN has a market cap of 13B. Regarding current trading prices, ABT is priced at $102.87, while PEN trades at $330.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas PEN's P/E ratio is 73.25. In terms of profitability, ABT's ROE is +0.13%, compared to PEN's ROE of +0.13%. Regarding short-term risk, ABT is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.Check PEN's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, ABT is priced at $102.87, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas SWAV's P/E ratio is 78.76. In terms of profitability, ABT's ROE is +0.13%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, ABT is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.Check SWAV's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, ALGN has a market cap of 12.2B. Regarding current trading prices, ABT is priced at $102.87, while ALGN trades at $170.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas ALGN's P/E ratio is 30.14. In terms of profitability, ABT's ROE is +0.13%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, ABT is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check ALGN's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, GMED has a market cap of 11.9B. Regarding current trading prices, ABT is priced at $102.87, while GMED trades at $87.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas GMED's P/E ratio is 22.43. In terms of profitability, ABT's ROE is +0.13%, compared to GMED's ROE of +0.12%. Regarding short-term risk, ABT is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check GMED's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, BIO-B has a market cap of 7.6B. Regarding current trading prices, ABT is priced at $102.87, while BIO-B trades at $280.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas BIO-B's P/E ratio is 10.06. In terms of profitability, ABT's ROE is +0.13%, compared to BIO-B's ROE of +0.11%. Regarding short-term risk, ABT is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.Check BIO-B's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, BIO has a market cap of 7.6B. Regarding current trading prices, ABT is priced at $102.87, while BIO trades at $279.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas BIO's P/E ratio is 10.05. In terms of profitability, ABT's ROE is +0.13%, compared to BIO's ROE of +0.11%. Regarding short-term risk, ABT is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check BIO's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, GKOS has a market cap of 6.5B. Regarding current trading prices, ABT is priced at $102.87, while GKOS trades at $112.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas GKOS's P/E ratio is -34.38. In terms of profitability, ABT's ROE is +0.13%, compared to GKOS's ROE of -0.25%. Regarding short-term risk, ABT is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check GKOS's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, BRKR has a market cap of 5.6B. Regarding current trading prices, ABT is priced at $102.87, while BRKR trades at $36.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas BRKR's P/E ratio is -245.07. In terms of profitability, ABT's ROE is +0.13%, compared to BRKR's ROE of -0.00%. Regarding short-term risk, ABT is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check BRKR's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, ABT is priced at $102.87, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas NARI's P/E ratio is -59.24. In terms of profitability, ABT's ROE is +0.13%, compared to NARI's ROE of -0.00%. Regarding short-term risk, ABT is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.Check NARI's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, IRTC has a market cap of 3.8B. Regarding current trading prices, ABT is priced at $102.87, while IRTC trades at $116.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas IRTC's P/E ratio is -84.03. In terms of profitability, ABT's ROE is +0.13%, compared to IRTC's ROE of -0.38%. Regarding short-term risk, ABT is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check IRTC's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, ABT is priced at $102.87, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas AXNX's P/E ratio is -709.80. In terms of profitability, ABT's ROE is +0.13%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, ABT is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.Check AXNX's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, LIVN has a market cap of 3.5B. Regarding current trading prices, ABT is priced at $102.87, while LIVN trades at $63.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas LIVN's P/E ratio is -14.33. In terms of profitability, ABT's ROE is +0.13%, compared to LIVN's ROE of -0.21%. Regarding short-term risk, ABT is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check LIVN's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, TMDX has a market cap of 3.5B. Regarding current trading prices, ABT is priced at $102.87, while TMDX trades at $100.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas TMDX's P/E ratio is 20.68. In terms of profitability, ABT's ROE is +0.13%, compared to TMDX's ROE of +0.54%. Regarding short-term risk, ABT is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check TMDX's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, ITGR has a market cap of 3B. Regarding current trading prices, ABT is priced at $102.87, while ITGR trades at $86.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas ITGR's P/E ratio is 30.05. In terms of profitability, ABT's ROE is +0.13%, compared to ITGR's ROE of +0.06%. Regarding short-term risk, ABT is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check ITGR's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, ABT is priced at $102.87, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas NUVA's P/E ratio is 75.00. In terms of profitability, ABT's ROE is +0.13%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, ABT is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check NUVA's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, AXGN has a market cap of 1.8B. Regarding current trading prices, ABT is priced at $102.87, while AXGN trades at $34.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas AXGN's P/E ratio is -101.29. In terms of profitability, ABT's ROE is +0.13%, compared to AXGN's ROE of -0.13%. Regarding short-term risk, ABT is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check AXGN's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, ESTA has a market cap of 1.7B. Regarding current trading prices, ABT is priced at $102.87, while ESTA trades at $58.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas ESTA's P/E ratio is -33.90. In terms of profitability, ABT's ROE is +0.13%, compared to ESTA's ROE of -2.02%. Regarding short-term risk, ABT is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check ESTA's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, ABT is priced at $102.87, while ATEC trades at $10.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas ATEC's P/E ratio is -11.28. In terms of profitability, ABT's ROE is +0.13%, compared to ATEC's ROE of -17.60%. Regarding short-term risk, ABT is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check ATEC's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, AORT has a market cap of 1.6B. Regarding current trading prices, ABT is priced at $102.87, while AORT trades at $34.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas AORT's P/E ratio is 162.90. In terms of profitability, ABT's ROE is +0.13%, compared to AORT's ROE of +0.02%. Regarding short-term risk, ABT is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check AORT's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, AHCO has a market cap of 1.6B. Regarding current trading prices, ABT is priced at $102.87, while AHCO trades at $12.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas AHCO's P/E ratio is -23.13. In terms of profitability, ABT's ROE is +0.13%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, ABT is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check AHCO's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, INSP has a market cap of 1.6B. Regarding current trading prices, ABT is priced at $102.87, while INSP trades at $54.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas INSP's P/E ratio is 11.25. In terms of profitability, ABT's ROE is +0.13%, compared to INSP's ROE of +0.21%. Regarding short-term risk, ABT is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check INSP's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, PMI has a market cap of 1.5B. Regarding current trading prices, ABT is priced at $102.87, while PMI trades at $0.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas PMI's P/E ratio is -1.27. In terms of profitability, ABT's ROE is +0.13%, compared to PMI's ROE of +2.17%. Regarding short-term risk, ABT is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check PMI's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, UFPT has a market cap of 1.5B. Regarding current trading prices, ABT is priced at $102.87, while UFPT trades at $192.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas UFPT's P/E ratio is 21.95. In terms of profitability, ABT's ROE is +0.13%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, ABT is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check UFPT's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, PRCT has a market cap of 1.4B. Regarding current trading prices, ABT is priced at $102.87, while PRCT trades at $25.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas PRCT's P/E ratio is -14.60. In terms of profitability, ABT's ROE is +0.13%, compared to PRCT's ROE of -0.25%. Regarding short-term risk, ABT is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check PRCT's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, ABT is priced at $102.87, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas HSKA's P/E ratio is -62.49. In terms of profitability, ABT's ROE is +0.13%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, ABT is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.Check HSKA's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, ABT is priced at $102.87, while TNDM trades at $18.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas TNDM's P/E ratio is -6.12. In terms of profitability, ABT's ROE is +0.13%, compared to TNDM's ROE of -1.42%. Regarding short-term risk, ABT is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check TNDM's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, ABT is priced at $102.87, while IRMD trades at $96.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas IRMD's P/E ratio is 54.99. In terms of profitability, ABT's ROE is +0.13%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, ABT is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check IRMD's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, ABT is priced at $102.87, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas SILK's P/E ratio is -18.96. In terms of profitability, ABT's ROE is +0.13%, compared to SILK's ROE of -0.35%. Regarding short-term risk, ABT is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.Check SILK's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, ABT is priced at $102.87, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas FNA's P/E ratio is -19.83. In terms of profitability, ABT's ROE is +0.13%, compared to FNA's ROE of -0.17%. Regarding short-term risk, ABT is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.Check FNA's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, ABT is priced at $102.87, while CNMD trades at $34.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas CNMD's P/E ratio is 23.04. In terms of profitability, ABT's ROE is +0.13%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, ABT is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check CNMD's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, BFLY has a market cap of 1B. Regarding current trading prices, ABT is priced at $102.87, while BFLY trades at $4.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas BFLY's P/E ratio is -13.26. In terms of profitability, ABT's ROE is +0.13%, compared to BFLY's ROE of -0.35%. Regarding short-term risk, ABT is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check BFLY's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, SSII has a market cap of 971.8M. Regarding current trading prices, ABT is priced at $102.87, while SSII trades at $5.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas SSII's P/E ratio is -83.33. In terms of profitability, ABT's ROE is +0.13%, compared to SSII's ROE of -0.30%. Regarding short-term risk, ABT is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check SSII's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, LMRI has a market cap of 884.2M. Regarding current trading prices, ABT is priced at $102.87, while LMRI trades at $9.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas LMRI's P/E ratio is -14.17. In terms of profitability, ABT's ROE is +0.13%, compared to LMRI's ROE of -0.18%. Regarding short-term risk, ABT is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check LMRI's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, INMD has a market cap of 873.7M. Regarding current trading prices, ABT is priced at $102.87, while INMD trades at $13.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas INMD's P/E ratio is 9.64. In terms of profitability, ABT's ROE is +0.13%, compared to INMD's ROE of +0.15%. Regarding short-term risk, ABT is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check INMD's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, ABT is priced at $102.87, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas CSII's P/E ratio is -20.83. In terms of profitability, ABT's ROE is +0.13%, compared to CSII's ROE of -0.14%. Regarding short-term risk, ABT is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.Check CSII's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, IART has a market cap of 742.7M. Regarding current trading prices, ABT is priced at $102.87, while IART trades at $9.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas IART's P/E ratio is -1.41. In terms of profitability, ABT's ROE is +0.13%, compared to IART's ROE of -0.44%. Regarding short-term risk, ABT is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check IART's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, ABT is priced at $102.87, while CRY trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas CRY's P/E ratio is 425.71. In terms of profitability, ABT's ROE is +0.13%, compared to CRY's ROE of +0.02%. Regarding short-term risk, ABT is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check CRY's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, CBLL has a market cap of 699M. Regarding current trading prices, ABT is priced at $102.87, while CBLL trades at $18.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas CBLL's P/E ratio is -12.63. In terms of profitability, ABT's ROE is +0.13%, compared to CBLL's ROE of -0.32%. Regarding short-term risk, ABT is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check CBLL's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, AVNS has a market cap of 648.7M. Regarding current trading prices, ABT is priced at $102.87, while AVNS trades at $13.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas AVNS's P/E ratio is -8.89. In terms of profitability, ABT's ROE is +0.13%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, ABT is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check AVNS's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, ABT is priced at $102.87, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas SRDX's P/E ratio is -34.66. In terms of profitability, ABT's ROE is +0.13%, compared to SRDX's ROE of -0.16%. Regarding short-term risk, ABT is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.Check SRDX's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, BVS has a market cap of 604.3M. Regarding current trading prices, ABT is priced at $102.87, while BVS trades at $8.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas BVS's P/E ratio is 27.18. In terms of profitability, ABT's ROE is +0.13%, compared to BVS's ROE of +0.14%. Regarding short-term risk, ABT is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check BVS's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, CTKB has a market cap of 582.3M. Regarding current trading prices, ABT is priced at $102.87, while CTKB trades at $4.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas CTKB's P/E ratio is -8.71. In terms of profitability, ABT's ROE is +0.13%, compared to CTKB's ROE of -0.18%. Regarding short-term risk, ABT is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check CTKB's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, ABT is priced at $102.87, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas APEN's P/E ratio is -9.43. In terms of profitability, ABT's ROE is +0.13%, compared to APEN's ROE of -0.85%. Regarding short-term risk, ABT is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.Check APEN's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, SIBN has a market cap of 579.4M. Regarding current trading prices, ABT is priced at $102.87, while SIBN trades at $13.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas SIBN's P/E ratio is -29.82. In terms of profitability, ABT's ROE is +0.13%, compared to SIBN's ROE of -0.11%. Regarding short-term risk, ABT is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check SIBN's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, TCMD has a market cap of 559.7M. Regarding current trading prices, ABT is priced at $102.87, while TCMD trades at $24.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas TCMD's P/E ratio is 30.00. In terms of profitability, ABT's ROE is +0.13%, compared to TCMD's ROE of +0.09%. Regarding short-term risk, ABT is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check TCMD's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, ABT is priced at $102.87, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, ABT's ROE is +0.13%, compared to ZIMV's ROE of -0.05%. Regarding short-term risk, ABT is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.Check ZIMV's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, BWAY has a market cap of 532.3M. Regarding current trading prices, ABT is priced at $102.87, while BWAY trades at $13.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas BWAY's P/E ratio is 75.39. In terms of profitability, ABT's ROE is +0.13%, compared to BWAY's ROE of +0.11%. Regarding short-term risk, ABT is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check BWAY's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, NPCE has a market cap of 493.2M. Regarding current trading prices, ABT is priced at $102.87, while NPCE trades at $14.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas NPCE's P/E ratio is -22.20. In terms of profitability, ABT's ROE is +0.13%, compared to NPCE's ROE of -1.06%. Regarding short-term risk, ABT is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check NPCE's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, OFIX has a market cap of 462.9M. Regarding current trading prices, ABT is priced at $102.87, while OFIX trades at $11.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas OFIX's P/E ratio is -4.95. In terms of profitability, ABT's ROE is +0.13%, compared to OFIX's ROE of -0.20%. Regarding short-term risk, ABT is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check OFIX's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, VREX has a market cap of 440.2M. Regarding current trading prices, ABT is priced at $102.87, while VREX trades at $10.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas VREX's P/E ratio is -6.40. In terms of profitability, ABT's ROE is +0.13%, compared to VREX's ROE of -0.14%. Regarding short-term risk, ABT is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check VREX's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, KIDS has a market cap of 406M. Regarding current trading prices, ABT is priced at $102.87, while KIDS trades at $16.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas KIDS's P/E ratio is -9.50. In terms of profitability, ABT's ROE is +0.13%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, ABT is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check KIDS's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, PACB has a market cap of 404.7M. Regarding current trading prices, ABT is priced at $102.87, while PACB trades at $1.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas PACB's P/E ratio is -0.74. In terms of profitability, ABT's ROE is +0.13%, compared to PACB's ROE of -11.23%. Regarding short-term risk, ABT is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check PACB's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, VMD has a market cap of 371.7M. Regarding current trading prices, ABT is priced at $102.87, while VMD trades at $9.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas VMD's P/E ratio is 26.03. In terms of profitability, ABT's ROE is +0.13%, compared to VMD's ROE of +0.11%. Regarding short-term risk, ABT is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check VMD's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, CERS has a market cap of 357.4M. Regarding current trading prices, ABT is priced at $102.87, while CERS trades at $1.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas CERS's P/E ratio is -23.25. In terms of profitability, ABT's ROE is +0.13%, compared to CERS's ROE of -0.26%. Regarding short-term risk, ABT is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check CERS's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, LAB has a market cap of 354.1M. Regarding current trading prices, ABT is priced at $102.87, while LAB trades at $0.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas LAB's P/E ratio is -6.05. In terms of profitability, ABT's ROE is +0.13%, compared to LAB's ROE of -0.18%. Regarding short-term risk, ABT is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check LAB's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, DCTH has a market cap of 334.6M. Regarding current trading prices, ABT is priced at $102.87, while DCTH trades at $9.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas DCTH's P/E ratio is 137.57. In terms of profitability, ABT's ROE is +0.13%, compared to DCTH's ROE of +0.03%. Regarding short-term risk, ABT is less volatile compared to DCTH. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check DCTH's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, CATX has a market cap of 324.9M. Regarding current trading prices, ABT is priced at $102.87, while CATX trades at $4.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas CATX's P/E ratio is -3.13. In terms of profitability, ABT's ROE is +0.13%, compared to CATX's ROE of -0.41%. Regarding short-term risk, ABT is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check CATX's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, ABT is priced at $102.87, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas SMLR's P/E ratio is 3.92. In terms of profitability, ABT's ROE is +0.13%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, ABT is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.Check SMLR's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, SENS has a market cap of 288.2M. Regarding current trading prices, ABT is priced at $102.87, while SENS trades at $6.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas SENS's P/E ratio is -4.16. In terms of profitability, ABT's ROE is +0.13%, compared to SENS's ROE of -1.04%. Regarding short-term risk, ABT is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check SENS's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, CLPT has a market cap of 278.7M. Regarding current trading prices, ABT is priced at $102.87, while CLPT trades at $9.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas CLPT's P/E ratio is -10.41. In terms of profitability, ABT's ROE is +0.13%, compared to CLPT's ROE of -1.22%. Regarding short-term risk, ABT is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check CLPT's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, RXST has a market cap of 274M. Regarding current trading prices, ABT is priced at $102.87, while RXST trades at $6.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas RXST's P/E ratio is -6.99. In terms of profitability, ABT's ROE is +0.13%, compared to RXST's ROE of -0.14%. Regarding short-term risk, ABT is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check RXST's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, MASS has a market cap of 247.1M. Regarding current trading prices, ABT is priced at $102.87, while MASS trades at $6.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas MASS's P/E ratio is -7.11. In terms of profitability, ABT's ROE is +0.13%, compared to MASS's ROE of +0.13%. Regarding short-term risk, ABT is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check MASS's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, ABT is priced at $102.87, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas MGRM's P/E ratio is -11.11. In terms of profitability, ABT's ROE is +0.13%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, ABT is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.Check MGRM's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, CVRX has a market cap of 237.1M. Regarding current trading prices, ABT is priced at $102.87, while CVRX trades at $9.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas CVRX's P/E ratio is -4.42. In terms of profitability, ABT's ROE is +0.13%, compared to CVRX's ROE of -0.99%. Regarding short-term risk, ABT is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check CVRX's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, ABT is priced at $102.87, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas NVRO's P/E ratio is -1.91. In terms of profitability, ABT's ROE is +0.13%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, ABT is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.Check NVRO's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, ANIK has a market cap of 213.4M. Regarding current trading prices, ABT is priced at $102.87, while ANIK trades at $14.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas ANIK's P/E ratio is -21.14. In terms of profitability, ABT's ROE is +0.13%, compared to ANIK's ROE of -0.07%. Regarding short-term risk, ABT is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check ANIK's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, ABT is priced at $102.87, while EYES trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas EYES's P/E ratio is N/A. In terms of profitability, ABT's ROE is +0.13%, compared to EYES's ROE of -3.17%. Regarding short-term risk, ABT is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check EYES's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, AVR has a market cap of 202.3M. Regarding current trading prices, ABT is priced at $102.87, while AVR trades at $5.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas AVR's P/E ratio is -2.16. In terms of profitability, ABT's ROE is +0.13%, compared to AVR's ROE of -5.28%. Regarding short-term risk, ABT is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check AVR's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, PROF has a market cap of 194.6M. Regarding current trading prices, ABT is priced at $102.87, while PROF trades at $6.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas PROF's P/E ratio is -4.56. In terms of profitability, ABT's ROE is +0.13%, compared to PROF's ROE of -0.80%. Regarding short-term risk, ABT is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check PROF's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, ELMD has a market cap of 194.3M. Regarding current trading prices, ABT is priced at $102.87, while ELMD trades at $23.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas ELMD's P/E ratio is 22.61. In terms of profitability, ABT's ROE is +0.13%, compared to ELMD's ROE of +0.20%. Regarding short-term risk, ABT is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check ELMD's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, ABT is priced at $102.87, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas BSGM's P/E ratio is -5.81. In terms of profitability, ABT's ROE is +0.13%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, ABT is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check BSGM's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, SGHT has a market cap of 190.1M. Regarding current trading prices, ABT is priced at $102.87, while SGHT trades at $3.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas SGHT's P/E ratio is -4.76. In terms of profitability, ABT's ROE is +0.13%, compared to SGHT's ROE of -0.56%. Regarding short-term risk, ABT is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check SGHT's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, ABT is priced at $102.87, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas MDGS's P/E ratio is -0.27. In terms of profitability, ABT's ROE is +0.13%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, ABT is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check MDGS's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, QTRX has a market cap of 177.9M. Regarding current trading prices, ABT is priced at $102.87, while QTRX trades at $3.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas QTRX's P/E ratio is -1.51. In terms of profitability, ABT's ROE is +0.13%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, ABT is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check QTRX's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, QTI has a market cap of 177.7M. Regarding current trading prices, ABT is priced at $102.87, while QTI trades at $6.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas QTI's P/E ratio is -3.26. In terms of profitability, ABT's ROE is +0.13%, compared to QTI's ROE of +3.64%. Regarding short-term risk, ABT is less volatile compared to QTI. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check QTI's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, INGN has a market cap of 169.1M. Regarding current trading prices, ABT is priced at $102.87, while INGN trades at $6.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas INGN's P/E ratio is -7.22. In terms of profitability, ABT's ROE is +0.13%, compared to INGN's ROE of -0.12%. Regarding short-term risk, ABT is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check INGN's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, ABT is priced at $102.87, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas QIPT's P/E ratio is -15.87. In terms of profitability, ABT's ROE is +0.13%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, ABT is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.Check QIPT's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, TLSI has a market cap of 160.7M. Regarding current trading prices, ABT is priced at $102.87, while TLSI trades at $4.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas TLSI's P/E ratio is -2.30. In terms of profitability, ABT's ROE is +0.13%, compared to TLSI's ROE of +1.37%. Regarding short-term risk, ABT is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check TLSI's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, APYX has a market cap of 153.9M. Regarding current trading prices, ABT is priced at $102.87, while APYX trades at $3.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas APYX's P/E ratio is -13.63. In terms of profitability, ABT's ROE is +0.13%, compared to APYX's ROE of -1.18%. Regarding short-term risk, ABT is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check APYX's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, NNOX has a market cap of 153.7M. Regarding current trading prices, ABT is priced at $102.87, while NNOX trades at $2.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas NNOX's P/E ratio is -2.74. In terms of profitability, ABT's ROE is +0.13%, compared to NNOX's ROE of -0.32%. Regarding short-term risk, ABT is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check NNOX's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, SNWV has a market cap of 145.2M. Regarding current trading prices, ABT is priced at $102.87, while SNWV trades at $16.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas SNWV's P/E ratio is 41.22. In terms of profitability, ABT's ROE is +0.13%, compared to SNWV's ROE of -1.42%. Regarding short-term risk, ABT is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check SNWV's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, EDAP has a market cap of 127.1M. Regarding current trading prices, ABT is priced at $102.87, while EDAP trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas EDAP's P/E ratio is -4.35. In terms of profitability, ABT's ROE is +0.13%, compared to EDAP's ROE of -1.15%. Regarding short-term risk, ABT is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check EDAP's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, LUCD has a market cap of 116.6M. Regarding current trading prices, ABT is priced at $102.87, while LUCD trades at $1.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas LUCD's P/E ratio is -1.65. In terms of profitability, ABT's ROE is +0.13%, compared to LUCD's ROE of -5.91%. Regarding short-term risk, ABT is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check LUCD's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, FONR has a market cap of 114.8M. Regarding current trading prices, ABT is priced at $102.87, while FONR trades at $18.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas FONR's P/E ratio is 16.17. In terms of profitability, ABT's ROE is +0.13%, compared to FONR's ROE of +0.04%. Regarding short-term risk, ABT is more volatile compared to FONR. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.Check FONR's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, ABT is priced at $102.87, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas ICAD's P/E ratio is -20.37. In terms of profitability, ABT's ROE is +0.13%, compared to ICAD's ROE of -0.06%. Regarding short-term risk, ABT is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.Check ICAD's competition here

ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ABT stands at 178.8B. In comparison, RPID has a market cap of 103.2M. Regarding current trading prices, ABT is priced at $102.87, while RPID trades at $2.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ABT currently has a P/E ratio of 27.65, whereas RPID's P/E ratio is -2.27. In terms of profitability, ABT's ROE is +0.13%, compared to RPID's ROE of -0.95%. Regarding short-term risk, ABT is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.Check RPID's competition here